Haemostasis interrupts bleeding from disrupted blood vessels by activating platelet aggregation and coagulation. A similar mechanism termed thrombosis generates obstructive thrombi inside diseased arteries. As a consequence of this similarity, current anti-thrombotic agents increase the risk of bleeding. Atherosclerotic plaques produce significant amounts of prostaglandin E 2 (PGE 2 ), which activates its receptor EP 3 on platelets and aggravates atherothrombosis. We investigated whether blocking EP 3 could dissociate atherothrombosis from haemostasis.
Introduction
Atherothrombosis, the leading cause of death worldwide, is partly prevented by current anti-platelet agents. 1 More potent drugs 2, 3 or drug combinations increase the risk of bleeding, 4 -6 and bleeding itself increases the risk of re-infarction and death. 7 Thus, there is a need for drugs able to intensify the anti-platelet effect without altering haemostasis, although the molecular mechanisms at play in haemostasis and thrombosis are highly intertwined. Some pathways involved in coagulation or platelet aggregation have been shown to predominate in thrombosis over haemostasis with the promise to reduce thrombotic events without increasing the bleeding risk. 1 Another strategy is to seek pro-thrombogenic factors that are produced in much higher amounts by atherosclerotic plaques than by healthy vascular wall. † These two authors contributed equally to the study.
Drugs targeting such factors could reduce atherothrombosis with a minor impact on haemostasis. Atherosclerotic plaques are inflammatory lesions 8 in which the arachidonic acid (AA) pathway is activated, producing for instance prostaglandin E 2 (PGE 2 ), 9 which activates its EP 2 , EP 3 , and EP 4 specific receptors on platelets. 10,11 EP 3 inhibits, 11, 12 whereas EP 2 and EP 4 activate, 13 -17 the adenylate cyclase. Both higher affinity of PGE 2 for EP 3 18 and murine in vivo models of thrombosis 11, 12 showed that the EP 3 -induced inhibition of adenylate cyclase predominates over EP 2 and EP 4 activations. So, PGE 2 globally decreases the intraplatelet production of cyclic AMP (cAMP), which itself inhibits calcium mobilization 19 triggered by conventional platelet activators, such as adenosine diphosphate (ADP), collagen, thrombin, or thromboxane A2 (TXA 2 ). Hence, PGE 2 increases platelet response, i.e. sensitizes platelets to its activators while alone it does not induce platelet aggregation. Specific inactivation of EP 3 synergizes with activation of EP 2 and EP 4 receptors by PGE 2 to increase the amount of intraplatelet cAMP that inhibits the platelet response. Consistent with this, we previously reported that in vivo murine atherothrombosis was drastically reduced by the lack of EP 3 on platelets. 9 We also previously observed that tail transection of EP 3 -deficient mice did not increase bleeding in mice. 12 Since human plaques produce PGE2, 20 these data suggest that targeting the PGE 2 /EP 3 pathway might prevent atherothrombosis without altering haemostasis. However, the lack of impact on murine haemostasis has been challenged, 11 the impact of PGE 2 on human platelets has been questioned, 21, 22 and demonstration that targeting the PGE 2 /EP 3 pathway dissociates thrombosis from haemostasis is lacking.
To test the hypothesis that atherothrombosis can be controlled without inducing bleeding in mice, we used a selective EP 3 blocker, DG-041, 23, 24 known to inhibit PGE 2 -induced potentiation of aggregation of rat 23, 24 and human platelets. 25 Using several models, the pharmacological EP 3 blockade reduced in vivo thrombosis, but did not alter haemostasis in several vascular beds. We showed that PGE 2 re-sensitized platelets in which the ADP pathway was blocked by clopidogrel, and that associating DG-041 to clopidogrel allowed the anti-thrombotic effect to be intensified without aggravating the clopidogrel-induced bleeding. Furthermore, we have shown here that PGE 2 was produced by human plaques, and that PGE 2 facilitated platelet aggregation in human whole blood. Finally, DG-041 inhibited human platelet aggregation, but not human bleeding time. These data show that blocking the PGE 2 /EP 3 pathway can reduce thrombosis without altering haemostasis.
Methods

Mice
Mouse procedures were approved by ethical committees (Strasbourg), conforming to the directive 2010/63/EU. Anaesthesia and euthanasia were performed with isoflurane. All experiments were performed by investigators blinded to treatments and/or genotypes (full methods in Supplementary material online).
Platelet aggregation tests
About 250 mL of platelet-rich plasma (PRP, 300 000 platelets/mL) isolated from citrated blood were used for aggregation tests; when indicated, platelets were incubated with DG-041 at 258C for 10 min.
Quantification of murine thrombosis by intravital macroscopy
Left carotid arteries of mice injected with calcein (300 ng/mL)-loaded platelets were exposed to either 4 mL of AA (100 mg/mL, 1 min) or ferric chloride 4% (1 mL, 5 min). Fluorescent thrombosis was video-recorded through a MacroFluo (Leica). 9 
Mouse model of atherothrombosis
Atherosclerotic plaques were scratched in blood flow using a tiny needle introduced through a branch of the external carotid artery (Figure 1 ).
Measurement of PGE 2 at the mouse site of bleeding
After amputating 5 mm of murine tail tips, another 3 mm wide piece was cut off for PGE 2 detection immediately vs. after bleeding cessation. PGE 2 was detected by Enzyme ImmunoAssay (EIA).
Quantification of murine blood loss
After amputating 7 mm of murine tail tips, surging blood was collected in distilled water (30 mL) up to bleeding cessation. Blood volume was determined from the OD 540 plotted against a calibration curve, corrected by blood haemoglobin.
Liver bleeding
In mice gavaged with vehicle, DG-041 (60mg/kg) or clopidogrel (10mg/kg), the median abdominal line was cut 1 h (water, DG-041) or 6 h (clopidogrel) after the gavage. A calibrated piece (3.90 + 0.15 mg, n ¼ 46) was chopped off from the inferior edge of the right lobe of the liver and the cavity closed. Red blood cells (RBCs) were counted in the 4 mL peritoneal lavage 20-min later.
Cerebral bleeding
A small borehole was drilled at 2 mm laterally to the bregma. A 25-G needle was lowered down to a 4 mm mark, rotated 3608, and removed. After euthanasia and transcardial perfusion 30-min later, the brain was extracted and cut (1 mm thickness). Haematoma was measured using Image J after deconvolution (fast red-fast blue-DAB; threshold: 160).
Determinations of murine bleeding time
To test DG-041 increasing doses, a transverse incision was made over the right lateral tail vein. Before AA-induced thrombosis, mice receiving clopidogrel or DG-041 had their 5 mm tail tips transected. In all these cases, the tail was immersed into phosphate buffered saline (378C). Bleeding times were measured from incision or transection to first cessation of bleeding.
Model of mouse pulmonary thromboembolism
Thirty minutes after gavaging mice with DG-041, 5 mL/kg of a solution combining a TXA 2 mimetic, U46619 (0.6 mmol/L), and the selective EP 3 agonist sulprostone (0.05 mg/mL) was injected via a lateral tail vein to induce intravenous thrombosis through the PGE 2 /EP 3 pathway. Survival was noted 60 min later.
Measurement of PGE 2 in human atherosclerotic plaques
Human carotid endarterectomy samples and non-atherosclerotic endarteries were obtained from patients undergoing carotid surgery or coronary bypass. These tissues, considered as surgical waste, were incubated for 24 h in a volume of Roswell Park Memorial Institute medium adjusted to the wet weight (6 mL/g of tissue) before performing EIA.
Blood sample collection from human subjects
Informed consent was obtained from healthy volunteers (20 -40 years old) in accordance with the Helsinki protocol from local bioethical committees (Strasbourg: CPP#09/504 or the National Bioethics Committee of Iceland). Fresh blood (venipuncture) was collected in citrated tubes from subjects not taking non-steroidal anti-inflammatory drugs.
Phosphorylated VAsodilator-Stimulated Phosphoprotein assay
Lysed platelets (radioimmunoprecipitation assay buffer) were used to measure protein concentration or phosphorylated VAsodilator-Stimulated Phosphoprotein (pVASP) by EIA. The EIA plates were coated with a monoclonal anti-VASP antibody (Immunoglobe); the primary antibody directed against pVASPSer157 (Santa Cruz) was revealed by a Horse Radish Peroxidase-a rabbit secondary antibody (DakoCytomation).
DG-041-CV-007 human clinical trial
This single-blind, randomized, placebo-controlled study (Institutional Review Board at the clinical site) studied three doses of DG-041 (100, 400, and 800 mg twice a day for 7 days). Ten healthy volunteers (18 -50 years old) were enrolled into each of the three cohorts. In each cohort, eight subjects were randomized to DG-041 and two to placebo. Bleeding times and platelet aggregation were measured at entry (pre-dose), and 4 h after the morning dose on the seventh day of treatment.
Human bleeding times
Under blood pressure maintained at 40 mmHg (local cuff), small punctures (1 mm wide and 3 mm deep) using Surgicutt w (ITC) were performed into the upper forearm of healthy individuals. Blood was blotted by the filter paper below the wound at 30-s intervals.
Statistics
Student's t-tests were bilateral and non-paired, except where otherwise indicated. The Mann-Whitney test was used when variances differed. The Kruskal -Wallis test followed by Dunn's post-test was used instead of one-way analysis of variance when the distribution was not Gaussian.
Means are expressed + SEM. A P-value of ,0.05 denoted significance. Tests were performed using the GraphPad Prism, Version 5.0, for Windows and SAS/STAT software, Version 9.
Results
Blocking the EP 3 receptor with DG-041 reduced murine thrombosis
Gavaging wild-type mice with DG-041 (60 mg/kg) dramatically inhibited the facilitating effect induced by PGE 2 (10.0 + 4.8%, n ¼ 7 vs. 60.4 + 6.0% of maximal aggregation, n ¼ 7 control mice), as efficiently as Ep3 2/2 platelets (see Supplementary material online, Figure S1 ). Furthermore, DG-041 inhibited thrombosis in vivo induced by AA or ferric chloride superfused on carotid arteries (see Supplementary material online, Figure S2 ). Moreover, we scratched the luminal surface of atherosclerotic plaques in Apoe 2/2 carotid arteries to provoke atherothrombosis. 9 DG-041 strikingly reduced the fluorescent atherothrombosis (0.02 + 0.01 × 10 5 pixels/min, n ¼ 12) observed in control mice (1.80 + 0.60 × 10 5 pixels/min, n ¼ 13, Figure 1 ).
Thus, the selective blockade of EP 3 inhibited murine thrombosis and atherothrombosis.
The PGE 2 /EP 3 pathway was not involved in murine haemostasis
To examine the role of the PGE 2 /EP 3 pathway in haemostasis, we first examined whether PGE 2 is produced in response to injury. After the amputation of tail tips (5 mm), PGE 2 amounts detected in the next 3 mm distal part of the tails were similar in samples taken upon beginning (555 + 72 pg/mg, n ¼ 5) vs. cessation (580 + 88 pg/mg, n ¼ 5, Figure 2A ) of bleeding. This lack of difference suggests that the cessation of bleeding did not require local production of PGE 2 . This basal amount of PGE 2 detected in the tail tissue does not interfere with the platelet function, since amputation of the tail tips did change the volume of blood loss neither in Ep3 2/2 mice (see Supplementary material online, Figure S3 ) nor in Apoe 2/2 mice of which plaques in carotid arteries were scratched. In the latters, the volumes of lost blood were not significantly different in mice treated with vehicle (128 + 30 mL, n ¼ 10), DG-041 (85 + 27 mL, n ¼ 10), or in sham-operated and age-matched WT mice (163 + 33 mL, n ¼ 10, Figure 2B ). We concluded that the PGE 2 /EP 3 pathway was not significantly involved in tail haemostasis.
Since haemostasis is tissue-specific, 26, 27 we further explored the impact of EP 3 blockade with DG-041 on liver and brain bleeding. After a calibrated piece of liver was chopped off from the inferior edge, the number of RBC in the peritoneal lavage did not change in mice gavaged with DG-041 (60 mg/kg) when compared with mice receiving water (1.04 + 0.39 × 10 5 RBC/mL, n ¼ 14 vs. 0.95 + 0.18 × 10 5 RBC/mL, n ¼ 15). Conversely, mice gavaged with 10 mg/kg clopidogrel lost significantly more blood (5.22 + 0.97 × 10 5 RBC/mL, n ¼ 17, Figure 2C ). To investigate the effect of EP 3 on brain haemostasis, we used a model of needle-induced intracerebral haemorrhage. 28 The extent of the cerebral haematoma was significantly increased only in mice receiving 10 mg/kg clopidogrel (22086 + 5475 red pixels, n ¼ 10), not in DG-041-(60 mg/kg) or water-gavaged mice (6864 + 1247 red pixels, n ¼ 13 vs. 4967 + 668 red pixels, n ¼ 10, Figure 2D ). Thus, blocking the EP 3 function did not alter tail, liver, or brain haemostasis.
High doses of DG-041 protected against pulmonary embolism, but maintained haemostasis
Next, we used a model of pulmonary thromboembolism to test whether haemostasis remains competent, although doses of DG-041 are increased. Almost all mice (86%) co-infused with sub-stimulating amounts of U46619 and sulprostone, an EP 3 agonist, died. This percentage dropped to 20% (n ¼ 15, Figure 3A -bottom) in the group of mice pre-treated with DG-041 at a dose of 10 mg/kg or greater. Conversely, bleeding induced by a calibrated transverse incision of the tail was unaltered by the EP 3 antagonist (88 + 7 s, n ¼ 27 receiving 100 mg/kg vs. 69 + 6 s, n ¼ 26 controls, Figure 3A -top). This experiment which involved a strong EP 3 stimulation clearly shows that increasing the doses of DG-041 decreased thrombosis, while haemostasis remained unchanged.
3.4 Activating the PGE 2 /EP 3 pathway restored the sensitivity of murine P 2 Y 12 -blocked platelets Since EP 3 activation decreases the cAMP platelet content and hence increases platelet sensitivity, we examined whether PGE 2 can resensitize platelets subjected to clopidogrel, which blocks the ADP receptor P 2 Y 12 to prevent thrombosis. 29 Platelets from mice gavaged with clopidogrel (5 mg/kg) and exposed to ADP (1 mmol/L) aggregated only in the presence of 10 26 M PGE 2 (3.81 + 0.69%, n ¼ 10 vs. 0.40 + 0.14%, n ¼ 10; Figure 3B ). Thus, PGE 2 partially restored the sensitivity of clopidogrel-treated platelets to ADP. Therefore, blocking the PGE 2 /EP 3 pathway should increase the anti-thrombotic effect induced by conventional platelet activators.
Blocking EP 3 intensified platelet inhibition without exacerbating bleeding
We next used the model of AA-induced thrombosis to test whether DG-041 can intensify platelet inhibition induced by clopidogrel. Clopidogrel at 2.5 mg/kg reduced thrombosis, but also significantly increased the bleeding time from 120 + 10 (controls, n ¼ 9) to 301 + 58 s (n ¼ 13, Figure 3C -top). Adding DG-041 to clopidogrel further decreased thrombotic scores from 10.72 + 2.46 × 10
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(n ¼ 14) to 3.12 + 1.13 × 10 5 pixels/min (n ¼ 13, Figure 3B -bottom), while the bleeding time did not significantly increase (279 + 52 s, n ¼ 15). To obtain a similar anti-thrombotic effect with clopidogrel alone, we had to increase the dose up to 10 mg/kg, which clearly exacerbated bleeding (463 + 51 s, n ¼ 13). Thus, blocking EP 3 intensified the platelet inhibition without worsening the bleeding induced by clopidogrel. This opens the possibility to dissociate thrombosis from haemostasis in vivo, at least in mice.
Human atherosclerotic plaques produced PGE 2
To examine whether this possibility to control thrombosis independently from haemostasis is clinically relevant, we first checked whether human atherosclerotic plaques produce PGE 2 . Carotid plaques or fragments of non-atherosclerotic endarteries collected from patients were incubated in adequate culture medium. The 24-h cumulative amounts of PGE 2 produced by stenotic (279 + 48 pg/mg, n ¼ 10) or non-stenotic (144 + 23 pg/mg, n ¼ 10) fragments of plaques were significantly higher than those yielded by fragments of non-atherosclerotic arteries (6.38 + 2.12 pg/mg, n ¼ 11, Figure 4A ). Thus, human plaques produce PGE 2 .
The PGE 2 /EP 3 pathway facilitated human platelet aggregation in whole blood
Since EP 3 gene sequences 30 and platelet expression 10, 11 are very close in mice and humans, platelet reactivity might be similar in both species. Indeed, PGE 2 facilitates in vitro human platelet aggregation in PRP. 31, 32 To check whether PGE 2 also facilitates platelet aggregation in whole blood, blood samples from nine healthy volunteers were subjected to the lowest dose of U46619 triggering a sub-maximal platelet aggregation (166 + 15 nmol/L). The adjunction of PGE 2 (10 27 mol/L) to this U46619 dose significantly increased the platelet aggregation ( Figure 4B) , showing that PGE 2 also facilitated platelet aggregation in human whole blood.
3.8 Activating the PGE 2 /EP 3 pathway restored the sensitivity of human P 2 Y 12 -blocked platelets
Next, we tested whether PGE 2 can restore the function of human platelets inhibited by standard medications. We obtained platelets from patients with peripheral arterial disease and medicated with aspirin (80 mg/day, n ¼ 6, ages 61 -74) or clopidogrel (75 mg/day, n ¼ 5, ages 48 -91), and from non-medicated control subjects (n ¼ 5, ages 66 -71). VASP, a cytoskeleton protein, is phosphorylated by cAMP/ cGMP kinases; pVASP is thus a marker of platelet cAMP levels. 33, 34 Thereby, the dephosphorylation of pVASP indicates a cAMP decrease resulting from platelet increased sensitivity or from platelet activation. As expected, adding ADP to ex vivo platelets dephosphorylated pVASP in platelets from control-or aspirin-treated patients, but not in those from clopidogrel-treated patients (93.6 + 18.5 vs. 32.1 + 4.8% in controls, Figure 4C ). In contrast, the EP 3 agonist sulprostone dephosphorylated pVASP in all platelet samples, including the group protected by clopidogrel (31.1 + 4.9 vs. 29.9 + 6.6% in controls). Thus, these human platelets subjected to standard oral anti-platelet treatments were re-sensitized by EP 3 activation. These results suggest that PGE 2 produced locally by the plaque can increase the sensitivity of platelets to their activators, even in patients receiving anti-platelet therapy.
3.9 Blocking EP 3 on human platelets inhibited the facilitating effect of PGE 2 and preserved haemostasis DG-041 potently inhibits EP 3 on human platelets (see Supplementary material online, Figure S4 ). In healthy volunteers ingesting DG-041 for 7 days, the twice-daily 100 mg dose abrogated the ex vivo platelet aggregation induced by sub-threshold collagen in the presence of 10 26 M 
Discussion
Atherothrombosis remains a clinical problem, partly because intensifying anti-thrombotic treatment exacerbates the risk of bleeding. 35 The PGE 2 /EP 3 pathway is of interest because PGE 2 , which facilitates the aggregation of activated platelets whatever the activator, 12 is produced in much larger quantities by atherosclerotic plaques than by healthy vascular walls. 9 Since we have previously demonstrated that PGE 2 is functional in plaques and activates its EP 3 receptor on platelets in the vicinity, 9 it
was not surprising that DG-041 reduced atherothrombosis. This effect results not only from the EP 3 blockade, but also from PGE 2 activation of EP 2 and EP 4 , which synergizes with the EP 3 blockade to increase the intraplatelet level of cAMP and to inhibit platelet function.
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The effect of EP 3 blockade on the scratching model confirms that the PGE 2 amount produced by plaque inflammation is sufficient to sensitize platelets. Moreover, it was not known whether it could re-sensitize platelets that have been blocked by conventional anti-platelet drugs. From the total amount of PGE 2 detected in Apoe 2/2 aorta, 9 the average number of plaques (10) in our 50-to 60-week-old mice and murine plaque volumes (0.1 -0.001 mL as measured by micro-CT 36, 37 ), we calculated that the PGE 2 concentration in murine plaques varies from 1 to .400 mmol/L. Here, 1 mmol/L of PGE 2 was sufficient to re-sensitize murine clopidogrel-blocked platelets, consistent with the decrease of pVASP observed in human clopidogrel-blocked platelets in response to sulprostone. Thus, plaque-produced PGE 2 can reduce the efficacy of conventional anti-platelet treatments, and platelets from clopidogrel-treated patients which appear insensitive to ADP in ex vivo clinical aggregation tests may actually become reactive on contact with ruptured atherosclerotic plaques, which release PGE 2 . These sensitizing and re-sensitizing effects of PGE 2 pinpoint the EP 3 receptor as an attractive target to control thrombosis.
Two previous studies showed opposed results on bleeding times in Ep 3 2/2 mice. 11, 12 Here, blocking EP 3 did not significantly alter bleeding times after tail transection or vein incision, neither did it alter blood loss after tail transection. Two other approaches (peritoneal RBC counting and brain slice imaging) led to the same conclusion. Based on these five different approaches in the three organs, we concluded that the PGE 2 /EP 3 pathway does not interfere with murine haemostasis. This is in agreement with our failure to detect any significant production of PGE 2 at the injury site; it is likely that inflammation is too slow a process to play any significant role in urgent haemostasis. Thus, targeting EP 3 should dissociate thrombosis from haemostasis in humans, provided that the mechanisms at play are similar.
The PGE 2 content of human lipid-rich plaques excised from atherosclerotic arteries was previously found too low to alter blood platelet function. 22 We similarly obtained negative results when we measured PGE 2 in isolated plaques. Conversely, we detected PGE 2 after mashing aortas immediately after harvest or while unfreezing, 9 which suggests that excising plaques from surrounding tissues degrade PGE 2 . Here, human plaques quickly immersed in culture media produced PGE 2 , demonstrating that they can produce it. The same authors 22 reported that PGE 2 did not alter human platelet aggregation in blood, as shown by the 5-min area under the curve (AUC). 21 We reproduced similar data (P ¼ 0.063); however, maximal aggregations at 5-and 8-min (ohms) and the 8-min AUC were significantly increased. This late response in some individuals may be due to initial higher cAMP platelet contents. Thus, PGE 2 is produced by human plaques, facilitates platelet aggregation in whole blood, and therefore can impact atherothrombosis. Consistent with the lack of any impact on murine haemostasis and in agreement with another recent study, 38 DG-041 up to 1600 mg/day (eight times the dose that inhibits the facilitating effect of PGE2 on platelets) did not alter the human bleeding time. Hence, blocking EP 3 opens the possibility to reduce thrombosis without altering haemostasis in humans.
Apart from aspirin, the efficacy of which is limited by bleeding, NSAIDs, or COX-2 blockers increased cardiovascular events in clinical trials, 39 -41 although they inhibit PGE 2 production. Actually, these drugs inhibit the entire prostaglandin pathway, unfavourably impacting the balance PGI 2 /TXA 2 and increasing blood pressure. 42 Conversely, blocking specifically the PGE 2 /EP 3 pathway should preserve other prostaglandin functions and avoid vasoconstriction. 43, 44 Blocking the production of PGE 2 will also inhibit its multiple physiological functions. Hence, blocking specifically the EP 3 receptor is an attractive strategy. The EP 3 receptor has been detected at significant levels in the kidneys, pancreas, adipocytes, and uterus, 45 but EP 3 -deficient mice did not display renal, metabolic, or fertility disorders. 46 In human volunteers (Clinical Study
Reports for trials DG-041-CV-007, DG-041-CV-008), neither renal function nor glucose levels were altered by DG-041 at doses up to 1600 mg daily for 28 days. Compared with other strategies developed to preserve haemostatic function, 1 targeting the PGE 2 /EP 3 pathway allows for the restriction of the anti-thrombotic effect to the plaque site, since plaques produce PGE 2 as opposed to the non-inflamed bleeding site. Since PGE 2 also reduces the protection conferred by clopidogrel, blocking the EP 3 receptor increases platelet inhibition at the ruptured site, where anti-thrombosis is crucial. To conclude, PGE 2 is produced by human atherosclerotic plaques and facilitated platelet function in human blood. Blocking EP 3 in mice or human volunteers inhibited platelet function while preserving haemostatic function. Thus, haemostasis and thrombosis differ by the selective involvement of the PGE 2 /EP 3 pathway, and therefore targeting the EP 3 receptor should increase the efficiency of conventional anti-platelet drugs without increasing the bleeding risk in myocardial infarction or strokes.
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